[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glatiramer.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Glatiramer.]
[L04AA27, fingolimod, Glatiramer may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Glatiramer.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Glatiramer.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Glatiramer.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Glatiramer.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Glatiramer is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Glatiramer.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Glatiramer.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Glatiramer.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Glatiramer.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Glatiramer.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Glatiramer.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Glatiramer.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Belimumab.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Glatiramer is combined with Belatacept.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Glatiramer.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Glatiramer.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Glatiramer.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Glatiramer.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Glatiramer is combined with Brentuximab vedotin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glatiramer.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Glatiramer.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Glatiramer.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Glatiramer is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Glatiramer.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Glatiramer.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Glatiramer.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Glatiramer.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Glatiramer is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Glatiramer.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Glatiramer is combined with Bendamustine.]
[L04AA29, tofacitinib, Glatiramer may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ponatinib.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Glatiramer is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Glatiramer is combined with Dimethyl fumarate.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Glatiramer.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ibrutinib.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Glatiramer.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Siltuximab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Vedolizumab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Glatiramer.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Glatiramer is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Glatiramer.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Glatiramer.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Olaparib.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Glatiramer is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Glatiramer.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Glatiramer.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Mepolizumab.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ixekizumab.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Glatiramer.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Glatiramer.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Brodalumab.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ocrelizumab.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Glatiramer.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Glatiramer.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Glatiramer.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Glatiramer.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Glatiramer.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Glatiramer.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Glatiramer.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Glatiramer.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Glatiramer.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Glatiramer.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Baricitinib.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Glatiramer.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ravulizumab.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Glatiramer is combined with Siponimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Glatiramer is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Glatiramer.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Glatiramer is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Risankizumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Upadacitinib.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Glatiramer is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Glatiramer.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Glatiramer is combined with Diroximel fumarate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Teprotumumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Glatiramer.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Glatiramer.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Glatiramer.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluprednidene.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Glatiramer is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Glatiramer.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Satralizumab.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Glatiramer.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Glatiramer is combined with Voclosporin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Glatiramer.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Glatiramer.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Glatiramer.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Glatiramer.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Glatiramer is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Glatiramer is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Anifrolumab.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ropeginterferon alfa-2b.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Deucravacitinib.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Glatiramer is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Glatiramer.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Glatiramer.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Glatiramer.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Glatiramer is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Glatiramer.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Glatiramer.]
[S01XA18, cyclosporine, Glatiramer may increase the immunosuppressive activities of Cyclosporine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Glatiramer.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Glatiramer.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Glatiramer.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Glatiramer.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glatiramer.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Glatiramer.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Glatiramer.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Glatiramer.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Glatiramer.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Glatiramer.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Glatiramer is combined with Pirarubicin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Glatiramer is combined with Difluocortolone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Glatiramer.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Glatiramer.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Glatiramer.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Glatiramer.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Glatiramer.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Glatiramer.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Glatiramer.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Glatiramer.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Glatiramer.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Glatiramer.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Glatiramer is combined with Trofosfamide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Glatiramer.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Glatiramer.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Glatiramer.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Glatiramer.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluticasone.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Glatiramer.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Glatiramer.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Glatiramer.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Glatiramer.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Glatiramer.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Glatiramer.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Glatiramer.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Glatiramer.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Glatiramer.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Glatiramer.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Glatiramer.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Glatiramer.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Glatiramer.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Glatiramer.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Glatiramer.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Glatiramer.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Glatiramer.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Glatiramer.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Glatiramer.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Glatiramer.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Glatiramer.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Glatiramer is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Glatiramer.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Glatiramer.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Glatiramer.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Glatiramer.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Glatiramer.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Glatiramer.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Tocilizumab.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Glatiramer.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Glatiramer.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Glatiramer.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Glatiramer is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Glatiramer is combined with Pralatrexate.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Glatiramer.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Glatiramer.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Glatiramer.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Glatiramer.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Glatiramer.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Glatiramer.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Glatiramer.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Glatiramer.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Glatiramer.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Glatiramer is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Glatiramer is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Glatiramer.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Glatiramer.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Glatiramer.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Glatiramer.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Glatiramer.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Glatiramer is combined with Rilonacept.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Glatiramer.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Glatiramer.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Glatiramer.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Glatiramer.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Glatiramer.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Glatiramer.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Golimumab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Canakinumab.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Glatiramer.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Glatiramer.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Glatiramer.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Glatiramer.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Glatiramer.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Glatiramer.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Glatiramer is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Glatiramer.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Glatiramer is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glatiramer.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Glatiramer is combined with Trastuzumab emtansine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Glatiramer is combined with Hydrocortisone butyrate.]
